Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

Phase 3amlenetugPositive

AI Analysis

Summary

Lundbeck will present Phase III MASCOT trial data for amlenetug in multiple system atrophy at the MDS 2026 conference, including late-breaking oral presentation characterizing the clinical profile and participant diversity of the ongoing global trial.

Clinical Trial Data

Phase

Phase III

Outcome Details

Late-breaking oral presentation of Phase III MASCOT trial data

Importance:6/10

Sentiment:

0.30

movement disordersmultiple system atrophyParkinson's diseaseclinical trialconference presentationMDS 2026

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Clinical Trials on October 2, 2026 6:31 AM

Read Original